Sec Form 3 Filing - Obrocea Mihail @ MAIA Biotechnology, Inc. - 2022-07-27

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Obrocea Mihail 2. Issuer Name and Ticker or Trading Symbol MAIA Biotechnology, Inc. [ MAIA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Medical Officer (Last) (First) (Middle) 444 WEST LAKE STREET, SUITE 1700 3. Date of Earliest Transaction (MM/DD/YY) 07/27/2022 (Street) CHICAGO, IL60606 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 26,100( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Options $ 1.8 ( 2 ) 01/05/2031 Common Stock 13,269 D Options $ 1.8 ( 2 ) 01/30/2031 Common Stock 6,131 D Options $ 1.83 ( 2 ) 04/04/2031 Common Stock 10,022 D Options $ 1.83 ( 3 ) 06/06/2031 Common Stock 7,447 D Options $ 1.83 ( 4 ) 06/04/2031 Common Stock 6,476 D Options $ 1.83 ( 5 ) 07/14/2031 Common Stock 260,000 D Option $ 1.83 ( 6 ) 06/29/2031 Common Stock 7,436 D Options $ 8 ( 7 ) 07/30/2031 Common Stock 772 D Warrants $ 6 ( 8 ) ( 8 ) Common Stock 8,820 D Warrants $ 6 ( 9 ) ( 9 ) Common Stock 4,230 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Obrocea Mihail 444 WEST LAKE STREET, SUITE 1700 CHICAGO, IL60606 Chief Medical Officer Signatures /s/ Mihail Obrocea 07/27/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Mr. Obrocea beneficially owns 26,100 shares of common stock. ( 2 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on May 11, 2021. ( 3 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on June 7, 2021. ( 4 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on June 5, 2021. ( 5 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. 25% of these options vest in 1 year with the remaining options vesting in 36 equal monthly installments beginning on July 15, 2021. ( 6 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on June 30, 2021. ( 7 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on July 31, 2021. ( 8 )Each Warrant became exercisable on the date of issuance of October 10, 2020, and expire on the earliest to occur of: (a) October 10, 2027 or (b) immediately prior to the closing of any change of control of the issuer. ( 9 )Each Warrant became exercisable on the date of issuance of June 29, 2021, and expire on the earliest to occur of: (a) June 28, 2028 or (b) immediately prior to the closing of any change of control of the issuer.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insuf ficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.